Abstract
From a comprehensive and systematic search of the relevant literature on signal data signature (SDS)-based artificial intelligence/machine learning (AI/ML) systems designed to aid in the diagnosis of COVID-19 illness, we aimed to reproduce the reported systems and to derive a performance goal for comparison to our own medical device with the same intended use. These objectives were in line with a pathway to regulatory approval of such devices, as well as to acceptance of this unfamiliar technology by disaster/pandemic decision makers and clinicians. To our surprise, none of the peer-reviewed articles or pre-print server records contained details sufficient to meet the planned objectives. Information amassed from the full review of more than 60 publications, however, did underscore discrete impediments to bringing AI/ML diagnostic solutions to the bedside during a pandemic. These challenges then were explored by the authors via a gap analysis and specific remedies were proposed for bringing AI/ML technologies in closer alignment with the needs of a Total Product Life Cycle (TPLC) regulatory approach.
Competing Interest Statement
K. Kelley, MD, FAADM, Chief Regulatory Medical Director for RAIsonance, Inc., A. A. Sakara, NP, MSN, RN, PHRN, Co-Chief for Clinical and Regulatory Affairs for RAIsonance, Inc., M. Kelley, MSN, RN, LNC, Co-Chief for Clinical and Regulatory Affairs for RAIsonance, Inc., S. C. Kelley, DNP, AGACNP-BC, FNP-BC, SVP Clinical Trials and Quality Improvement for RAIsonance, Inc. P. McLenaghan, MBA, SVP Market and Business Development for RAIsonance, Inc., R. Aldir, MD, FACC, Chairperson Healthcare Provider Advisory Board for RAIsonance, Inc. M. Cox - Lead AI/ML Biotechnical Engineer for RAIsonance, Inc., N. Donaldson - AI/ML Biotechnical Engineer for RAIsonance, Inc., A. Stogsdill - AI/ML Biotechnical Engineer for RAIsonance, Inc., S. Kotchou - AI/ML Biotechnical Engineer for RAIsonance, Inc., G. Sula, Intern at RAIsonance, Inc., M. A, Ramirez, DO, PhD, Chief Medical Officer, Chief Scientist, Chief Strategy and Planning Officer for RAIsonance, Inc
Funding Statement
RAIsoance, Inc
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The SDS libraries, including Coswara, Virufy, COUGHVID and IATos are all open source COVID- cough libraries available online.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Dedicated to Our Respected Fellow AI/ML COVID-19 Signal Data Signature Researchers and Healthcare Decision Makers who have died of COVID-19: M. Maleki and M.E. Thornton.
Data Availability
All data produces is available upon request from the authors
